The stock of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) is a huge mover today! About 215,821 shares traded hands or 155.56% up from the average. Ritter Pharmaceuticals Inc (NASDAQ:RTTR) has risen 14.72% since March 15, 2016 and is uptrending. It has outperformed by 9.24% the S&P500.
The move comes after 8 months positive chart setup for the $19.93M company. It was reported on Oct, 18 by Barchart.com. We have $4.30 PT which if reached, will make NASDAQ:RTTR worth $20.73M more.
Analysts await Ritter Pharmaceuticals Inc (NASDAQ:RTTR) to report earnings on November, 15.
Ritter Pharmaceuticals Inc (NASDAQ:RTTR) Ratings Coverage
Out of 2 analysts covering Ritter Pharmaceuticals (NASDAQ:RTTR), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ritter Pharmaceuticals has been the topic of 2 analyst reports since December 2, 2015 according to StockzIntelligence Inc. The rating was initiated by Maxim Group with “Buy” on Thursday, April 14. Chardan Capital Markets initiated the stock with “Buy” rating in Wednesday, December 2 report.
According to Zacks Investment Research, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California.”
More important recent Ritter Pharmaceuticals Inc (NASDAQ:RTTR) news were published by: Quotes.Wsj.com which released: “News Ritter Pharmaceuticals Inc.RTTR” on June 13, 2015, also Businesswire.com published article titled: “Ritter Pharmaceuticals Appoints AnnKatrin Petersen-Jappelli, M.D., M.SC. as …”, Businesswire.com published: “Ritter Pharmaceuticals Appoints William J. Sandborn, M.D. to Medical Advisory …” on October 21, 2015. More interesting news about Ritter Pharmaceuticals Inc (NASDAQ:RTTR) was released by: Businesswire.com and their article: “Ritter Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering” with publication date: June 24, 2015.
RTTR Company Profile
Ritter Pharmaceuticals, Inc., incorporated on October 16, 2008, develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Firm conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.